Significantly, ARID1A loss did not correlate with clinical outcomes, stage, age, or CD8+ tumor-infiltrating lymphocyte (TIL) levels in either histotype, suggesting that while ARID1A mutation is a key molecular event in tumorigenesis, it lacks prognostic significance [135]. Here, ARID1A is linked to neoplasm.